Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.

Changes in the percent of positive opioid tests also varied by indication group attaining marginal significance (phase × group: F [2,39] = 3.2, p = .05).

also in 5,069 other papers

Although the total fraction of UDS tests that were positive (for any substance) trended downward for both groups with opioid disorders from the pre‐ to post‐injection phases (analyzed for the n = 43 patients who had UDS tests in both the pre‐ and post‐injection phases) (Table 3 ), these changes only approached significance (phase: F [1,40] = 3.0, p = .09, NS); group: F [2,40] = 1.5, NS; group × phase F [2, 40] = 2.5, p = .09, NS).

also in 8,237 other papers